SECOND EULAR COURSE ON
SYSTEMIC LUPUS ERYTHEMATOSUS
San Miniato, Italy – September 4 – 9, 2005
PROGRAM
|
| SUNDAY 4 SEPTEMBER 2005 |
| 17.30-18.00 |
S. Bombardieri |
Presentation of
the Course |
| 18.00-19.00 |
G.R.V. Hughes |
Lupus in 2005. Success and
failure. |
|
| MONDAY 5 SEPTEMBER 2005 |
| Pharmacodynamics and pharmacokinetics
of traditional and new drugs in SLE |
| 08.30-08.50 |
M. Del Tacca |
Introduction |
| 08.50-09.20 |
R. Danesi |
Pharmacogenomics: a key for
understanding drugs response in SLE |
| 09.50-10.20 |
G. Ferraccioli |
Pharmacogenomics and SLE: the
example of Methotrexate and Azatioprine |
| 10.20-10.50 |
M. Cutolo |
Corticosteroids and SLE
|
| 10.50-11.15 |
|
Break |
| 11.15-11.45 |
F. Houssiau |
Cyclophosphamide and SLE |
| 11.45-12.15 |
A. Doria |
Mycophenolate mofetil and SLE |
| 12.15-12.45 |
P.L. Meroni |
Statins, anticoagulant and
antithrombotic drugs |
|
| Therapy of SLE: safety |
| 14.30-15.00 |
O. Di Munno |
Drug therapy and
osteoporosis in SLE |
| 15.00-15.30 |
A.G. Tzioufas |
Drug therapy and prevention
of infertility in SLE |
| 15.30-16.00 |
A. Tincani |
Drug therapy and toxicity in
pregnancy and lactation in SLE |
| 16.00-16.30 |
G. Valesini |
Drugs interactions in SLE |
| 16.30- 17.00 |
A. Tyndall |
Stem cell transplantation in
SLE and other autoimmune diseases |
|
| TUESDAY 6 SEPTEMBER 2005 |
| Kidney involvement |
| 08.30-09.00 |
J. Berden |
Role of anti-chromatin
autoantibodies in the pathogenesis of lupus nephritis |
| 09.00-09.30 |
P. Migliorini |
Other pathogenetic antibodies
in lupus nephritis |
|
| Clinical picture and monitoring: |
| 09.30-10.00 |
C. Ponticelli |
Histological and clinical features of lupus nephritis
|
| 10.00-10.30 |
G. Moroni |
Optimizing the clinical monitoring of lupus nephritis
and evaluation of prognostic factors in lupus nephritis
|
| 10.30-11.00 |
D. Boumpas |
Therapeutic algorhytms in lupus
nephritis |
| 11.00-11.30 |
|
Break |
| 11.30-13.00 |
|
Discussion of clinical cases |
|
| Particular issues |
| 14.30-15.00 |
M.A. Khamashta |
Pregnancy and SLE |
| 15.00-15.30 |
F. Conti |
Vaccination in SLE |
| 15.30-16.00 |
C.M. Montecucco |
Fever and SLE |
| 16.00-16.30 |
M. Mosca |
Undifferentiated connective
tissue diseases |
|
| WEDNESDAY 7 SEPTEMBER 2005 |
| CNS involvement |
| 08.30-09.00 |
G. Riemekasten |
Pathogenesis of
central nervous system involvement in SLE |
|
| Clinical pictures: |
| 09.00-09.30 |
J.C. Piette |
Neurological manifestations of CNS involvement in
SLE
|
| 09.30-10.00 |
D. D’Cruz |
Fatigue and psychiatric manifestations in SLE.
|
| 10.00-10.30 |
M. Govoni |
Optimizing the diagnosis and the clinical monitoring
of CNS involvement in SLE
|
| 10.30-11.00 |
T. Huizinga |
Therapeutic algorhytms of neurological involvement
in SLE.
|
| 11.00-11.30 |
|
Break
|
| 11.30-13.00 |
|
Discussion of clinical cases |
| Afternoon |
|
FREE |
|
| THURSDAY 8 SEPTEMBER 2005 |
| Therapy of SLE: From bench
to the bedside |
| 09.00-10.00 |
J. Kalden: |
Pathogenesis as
a clue for targeted therapies for SLE |
| 10.00-10.30 |
M. Aringer |
Prospects of biological therapies
in SLE |
| 10.30-11.00 |
J.S. Smolen |
Rituximab, CTLA4-Ig and peptide
treatment in SLE |
| 11.00-11.30 |
|
Break |
| 11.30-12.00 |
M. Galeazzi |
Causes of death in SLE |
| 12.00-12.45 |
R.J.T. Smeenk |
Autoantibodies in clinical
practice in SLE patients |
|
| Skin manifestation |
| 14.30-15.00 |
R. Rondinone |
Diagnosis and differential diagnosis of cutaneous
involvement in SLE
|
| 15.00-15.30 |
A. Kuhn |
Treatment of cutaneous involvement in SLE
|
| 15.30-17.00 |
|
Discussion of clinical cases |
|
| FRIDAY 9 SEPTEMBER 2005 |
Measures to assess and
monitoring a patient with SLE and response to therapy:
creation of a data base for SLE patients |
| 08.30-09.00 |
S. Bombardieri |
The evaluation of patients with SLE
|
| 09.00-09.30 |
C. Gordon |
The assessment of quality of
life in SLE |
| 09.30-10.00 |
M. Schneider |
Development of a responder
Index for SLE |
| 10.00-10.30 |
K. Manger |
Diagnostic factors |
| 10.30-11.00 |
M. Liang |
The core set variables to monitor
patients with SLE |
| 11.00-11.30 |
|
Break |
| 11.30-12.00 |
R. Cervera |
Haematological manifestations
of SLE |
| 12.00-12.45 |
Y. Shoenfeld |
Atherosclerosis and autoimmunity:
the example of SLE |
| Afternoon |
|
|
| 14.30-15.00 |
|
Report of the results of a questionnaire
on renal involvement |
| 15.00-15.30 |
|
Report of the results of a
questionnaire on cutaneous involvement |
| 15.30-16.00 |
|
Report of the results of a
questionnaire on neurological involvement |
|
|
Credits and departures
|
